Here's Why AtriCure Stock Is Moving Today

AtriCure Inc. ATRC shares are trading higher by 6.35% at $69.03 after the company reported better-than-expected first-quarter EPS and sales results.

Oppenheimer analyst Suraj Kalia maintains AtriCure with an Outperform and raises the price target from $65 to $75.

Needham analyst Mike Matson also maintains AtriCure with a Buy and raises the price target from $74 to $81.

AtriCure is an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation.